Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.

Intended setting of use for genitourinary cancer drug approvals by tumor type, 2020-2024. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...

ITP - ifosfamide, paclitaxel, and cisplatin; EP – etoposide/platinum; IA-EP – ifosfamide/Adriamycin-EP; Gem-FLP – gemcitabine, 5-FU, leucovorin, cisplatin. This is an ASCO Meeting Abstract from the ...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including three accepted ...

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...